ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway - PubMed
8 hours ago
- #ADAMTS13
- #diabetic nephropathy
- #oxidative stress
- ADAMTS13 levels are reduced in diabetic nephropathy (DN) patients.
- Recombinant human ADAMTS13 (rhADAMTS13) inhibits reactive oxygen species (ROS) by activating the Nrf2/GPX4 pathway.
- ADAMTS13 reduces mitophagy and ferroptosis, alleviating renal injury in DN mice.
- ADAMTS13 enhances eNOS phosphorylation, increasing nitric oxide (NO) production and improving endothelial dysfunction.
- In vitro, rhADAMTS13 decreases ROS in cytoplasm and mitochondria while reducing NO release.
- ADAMTS13 may be a therapeutic target for DN via the Nrf2/GPX4/eNOS signaling pathway.